Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its target price upped by stock analysts at HC Wainwright from $30.00 to $35.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 53.51% from the stock’s current price.

A number of other equities analysts have also commented on CPRX. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective for the company. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 3rd. Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday. Finally, Truist Financial boosted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $32.86.

Catalyst Pharmaceuticals Stock Up 16.7 %

Shares of NASDAQ CPRX opened at $22.80 on Friday. The company has a market cap of $2.72 billion, a P/E ratio of 19.32, a P/E/G ratio of 3.35 and a beta of 0.79. Catalyst Pharmaceuticals has a 52 week low of $13.12 and a 52 week high of $24.27. The business has a 50-day simple moving average of $21.75 and a two-hundred day simple moving average of $19.88.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 681 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals in the third quarter valued at about $50,000. Larson Financial Group LLC raised its stake in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter worth about $70,000. Finally, Quantbot Technologies LP bought a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth about $151,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.